Clinical Trial Update: Trastuzumab Deruxtecan(T-DXd) and Afatinib Combination in HER2-low Advanced Gastric Cancer [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating the combination of trastuzumab deruxtecan and afatinib for HER2-low advanced gastric cancer is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer

Drugs mentioned

• Afatinib (afatinib)
• Trastuzumab deruxtecan (trastuzumab deruxtecan)

Snippet

Sponsor: Jeeyun Lee | Conditions: Stomach Neoplasm | Phase 1, Phase 2 | Status: RECRUITING